# CERVINO (NCT06158841)

> Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06158841
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Multiple Myeloma
- Interventions: Etentamig; Carfilzomib; Pomalidomide; Elotuzumab; Selinexor; Bortezomib; Dexamethasone
- Enrollment: 421
- Primary outcome: Progression Free Survival (PFS)
- Primary outcome: Objective Response Rate (ORR)

## Commentary we found

- X threads: 51
- YouTube: 8
- Podcasts: 1
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cervino-nct06158841

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06158841", "email": "<work email>"}; the inbox owner confirms by the emailed link.